

Prolyl 4-hydroxylase (P4H) Inhibitor – DMOG

Chemical Name: methyl 2-((2-methoxy-2-oxoethyl)amino)-2-oxoacetate

 $\sim \frac{1}{2} \frac{$

Molecular Weight:	175.14
Formula:	C ₆ H ₉ NO ₅
Purity:	≥98%
CAS#:	89464-63-1
Solubility:	DMSO up to 100 mM
	Water up to 100 mM
Storage	Powder: 4°C 1 year
	DMSO: 4°C 3 month
	-20°C 1 year

Biological Activity:

DMOG is a selective, competitive and cell permeable prolyl 4-hydroxylase (P4H) inhibitor. It inhibits hypoxia-inducible factor α (HIF- α) prolyl hydroxylase (HIF-PH). It acts to stabilize HIF-1 α expression at normal oxygen tensions in cultured cells, at concentrations between 0.1 and 1 mM. DMOG acts as a proangiogenic compound, acting via the HIF-1 α system.

How to Use:

In vitro: DMOG was used at $100 \ \mu$ M final concentration in vitro and in cellular assays.

In vivo: n/a

Reference:

- 1. Jaakkola P, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. (2001) Science. 292(5516):468-72.
- Lomb DJ, et al. Prolyl hydroxylase inhibitors depend on extracellular glucose and hypoxia-inducible factor (HIF)-2alpha to inhibit cell death caused by nerve growth factor (NGF) deprivation: evidence that HIF-2alpha has a role in NGF-promoted survival of sympathetic neurons. (2009) Mol Pharmacol. 75(5):1198-209.
- 3. Ayrapetov MK, et al. Activation of Hiflα by the prolylhydroxylase inhibitor dimethyoxalyglycine decreases radiosensitivity. (2011) PLoS One. 6(10):e26064.
- 4. Barnucz E, et al. Prolyl-hydroxylase inhibition preserves endothelial cell function in a rat model of vascular ischemia reperfusion injury. (2013) J Pharmacol Exp Ther. 345(1):25-31.

Products are for research use only. Not for human use.